CME/CE

CME/CE

By ReachMDMedicine
Download on the App Store

CME/CE episodes

  • Emerging Therapies in Managing Adult and Pediatric Patients With FSGS: Latest Data
    Faculty: Vladimir Tesar
    Faculty: Meghan Sise, MD

    Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

    6 min
  • Monitoring FSGS: Traditional and Novel Biomarkers
    Faculty: Meghan Sise, MD
    Faculty: Vladimir Tesar

    Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

    6 min
  • Current FSGS Treatment Landscape: More Questions Than Answers
    Faculty: Vladimir Tesar
    Faculty: Meghan Sise, MD

    Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

    6 min
  • FSGS: When Solutions Fall Short
    Faculty: Meghan Sise, MD

    Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

    6 min
  • FSGS: Interpretation of Proteinuria Reduction Thresholds
    Faculty: Vladimir Tesar
    Faculty: Meghan Sise, MD

    Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

    6 min
  • DEARA Versus SOC in FSGS Management: Clinical Trial Insights
    Faculty: Vladimir Tesar
    Faculty: Meghan Sise, MD

    Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

    6 min
  • Treatment Considerations for Pediatric Patients With FSGS
    Faculty: Kenneth Lieberman, MD

    Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

    6 min
  • Future Directions in FSGS Care
    Faculty: Kenneth Lieberman, MD
    Faculty: Vladimir Tesar

    Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

    7 min
  • Bronchiectasis Update: Diagnostic Innovations and Therapeutic Frontiers
    Host: Christopher J. Richards, MD
    Host: Ashley Losier, MD

    Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn to distinguish bronchiectasis from other respiratory conditions and assess patient risk factors that impact outcomes. This module covers how pulmonary exacerbations influence disease course and highlights new insights from recent clinical trials. Stay ahead of the curve with updates on emerging therapies that could transform how we manage this challenging disease.

    54 min
  • Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications
    Faculty: Marion Munk, MD, Ph.D
    Faculty: David Boyer, MD

    This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

    7 min

About CME/CE

From the publisher's feed

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes,…